The California biotech is shrinking its head count by 40% and reassessing the future of Amgen-partnered T-cell engager CX-904 as a way to save cash and focus on its lead antibody-drug conjugate.

The FDA thinks an antibody-drug conjugate (ADC) developed by AbbVie could set new standards in treatment for certain patients with lung cancer, awarding the drug breakthrough status. Teliso-V ...

Two years after AstraZeneca splashed out $1 billion upfront for rights to Daiichi Sankyo's TROP2-targeting antibody-drug conjugate DS-1062, the drug has generate promising results in advanced non ...

A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We're maintaining the criteria we used for last ...

Site-specific endonucleases that exclusively cut single-stranded DNA have hitherto never been described and constitute a barrier to the development of ssDNA-based technologies. Here the authors ...

After hours: March 20 at 7:43:41 PM EDT Loading Chart for VOR ...

After hours: March 19 at 4:51:27 PM EDT Loading Chart for PDSB ...

Berlin (EFE).- Germany's federal parliament (Bundestag) approved a constitutional reform on Tuesday that will allow a historic increase in defense spending to rearm the country. The conservative ...

Your help is vital for us to continue our work. Stop the War opposes the British establishment’s disastrous addiction to war. #CeasefireNow in Gaza & Ukraine. Stop Arming Israel.